ERibulin in Advanced Solitary fibrous tumor, an ItaliaN sarcoma Group phase II study (ERASING)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517795-38-00

Acronym

ISG-ERASING

Enrollment

Registered

2024-10-01

Start date

2019-06-26

Completion date

2025-10-13

Last updated

2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solitary fibrous tumor

Brief summary

Overall tumor Response Rate, according to RECIST v 1.1

Detailed description

Choi Response Rate, Overall Survival (OS), Progression Free Survival (PFS), Clinical Benefit Rate, Duration of response, Safety

Interventions

DRUGHALAVEN 0.44 mg/ml solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall tumor Response Rate, according to RECIST v 1.1	—

Secondary

Measure	Time frame
Choi Response Rate, Overall Survival (OS), Progression Free Survival (PFS), Clinical Benefit Rate, Duration of response, Safety	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026